Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Our Bureau

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic treatment for the bleeding disorder Glanzmann Thrombasthenia (Glanzmann). The data […]

Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)

Our Bureau

Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunizeda pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab is currently the only therapy reported to be in […]

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

Our Bureau

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent […]

Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing

Our Bureau

Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies is moving forward with its appetite suppression supplement, TPT0701. Modulation of the endocannabinoid system has long been recognized as a promising way to regulate appetite. Through intensive research […]

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Our Bureau

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company’s manufacturing and supply […]

Persistent Launches Population Health Management Solution Using Microsoft Azure OpenAI Service

Our Bureau

Persistent Systems (BSE: PERSISTENT) and (NSE: PERSISTENT), a global Digital Engineering and Enterprise Modernization leader, today launched an innovative Generative AI-powered Population Health Management (PHM) Solution in collaboration with Microsoft. Aligned with value-based care models, the Solution identifies Social Determinants of Health (SDoH) to determine patients’ non-clinical needs and better predict the cost […]

Cathay Biotech and 3P.COM Signed Joint Venture Agreement to Propel Sustainable Composite Innovations

Our Bureau

Cathay Biotech Inc. (“Cathay”) and 3P.COM Co. Limited (“3P.COM”) signed a strategic joint venture agreement on January 16, 2024, in Shanghai, P.R.China. The collaboration will focus on advancing the development of bio-based polyamide thermoplastic composites tailored for critical applications such as hydrogen storage and transportation, urban air transport, and wind turbine blades. […]

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy

Our Bureau

 Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, is pleased to announce the Health Canada approval of MYALEPTA™ (metreleptin for injection). As an adjunct to diet, MYALEPTA is indicated as a replacement therapy to […]

Uncle Bud’s to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

Our Bureau

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is hosting a teleconference today (Monday, […]

Subscribe Now